What is Chardan Capital’s Forecast for FBRX FY2025 Earnings?

Forte Biosciences, Inc. (NASDAQ:FBRX) – Chardan Capital upped their FY2025 EPS estimates for Forte Biosciences in a research report issued on Monday, November 17th. Chardan Capital analyst D. Gataulin now anticipates that the company will post earnings of ($4.40) per share for the year, up from their prior estimate of ($5.00). Chardan Capital has a “Buy” rating and a $61.00 price target on the stock. The consensus estimate for Forte Biosciences’ current full-year earnings is ($12.12) per share. Chardan Capital also issued estimates for Forte Biosciences’ FY2026 earnings at ($3.28) EPS.

FBRX has been the subject of several other research reports. Guggenheim assumed coverage on shares of Forte Biosciences in a research report on Monday, August 18th. They set a “buy” rating and a $75.00 price objective for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Forte Biosciences in a report on Friday, October 31st. Finally, Wall Street Zen downgraded Forte Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $68.00.

Forte Biosciences Price Performance

NASDAQ FBRX opened at $18.71 on Thursday. Forte Biosciences has a one year low of $4.90 and a one year high of $28.68. The firm has a market cap of $234.44 million, a P/E ratio of -5.64 and a beta of 2.98. The stock’s 50-day moving average is $13.48 and its 200-day moving average is $11.56.

Forte Biosciences (NASDAQ:FBRX) last posted its earnings results on Friday, November 14th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.05.

Institutional Investors Weigh In On Forte Biosciences

Several large investors have recently made changes to their positions in the stock. Bank of America Corp DE lifted its stake in Forte Biosciences by 5,641.8% in the third quarter. Bank of America Corp DE now owns 3,158 shares of the company’s stock valued at $47,000 after acquiring an additional 3,103 shares during the last quarter. AlphaQuest LLC bought a new position in Forte Biosciences during the first quarter worth about $33,000. Dimensional Fund Advisors LP acquired a new position in Forte Biosciences during the third quarter worth approximately $161,000. Citadel Advisors LLC bought a new stake in Forte Biosciences in the third quarter valued at approximately $234,000. Finally, Envestnet Asset Management Inc. bought a new stake in Forte Biosciences in the second quarter valued at approximately $244,000. Institutional investors and hedge funds own 77.63% of the company’s stock.

Forte Biosciences Company Profile

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.